 Reduction incidence inducible ventricular tachycardia myocardial infarction treatment streptokinase infarct evolution aim study intravenous streptokinase oral aspirin patients myocardial infarction inducibility ventricular tachycardia electrophysiologic study risk sudden death infarct survivors patients Westmead Hospital multicenter Second International Study Infarct Survival streptokinase aspirin acute myocardial infarction underwent electrophysiologic days infarction risk subsequent ventricular arrhythmias streptokinase patients patients streptokinase aspirin patients patients Patients electrophysiologic testing similar clinical characteristics patients stimulation protocol extrastimuli right ventricular apex diastolic threshold abnormal result ventricular tachycardia cycle length equal ms equal Ventricular tachycardia inducible electrophysiologic study patients placebo streptokinase patient active streptokinase versus Fischer exact test Ventricular tachycardia inducible patients aspirin therapy versus NS mean follow-up period months spontaneous episodes ventricular tachycardia ventricular fibrillation sudden death streptokinase-treated group events placebo-treated group placebo therapy intravenous streptokinase incidence inducible ventricular tachycardia infarct survivors similar benefit attributable therapy